Teva Pharma (TEVA) Tops Q4 EPS by 31c, Beats on Revenue; Offers FY26 Revenue Guidance

Teva Pharma (NYSE: TEVA) reported Q4 EPS of $0.96, $0.31 better than the analyst estimate of $0.65. Revenue for the quarter came in at $4.71 billion versus the consensus estimate of $4.33 billion.

GUIDANCE:

Teva Pharma sees FY2026 revenue of $16.4-16.8 billion, versus the consensus of $16.9 billion.

For earnings history and earnings-related data on Teva Pharma (TEVA) click here.

You May Also Be Interested In

• BofA lists top 5 themes driving next $1tn in incremental semi sales
• Tetra4 signs first helium supply deal for South Africa gas project
• Bandwidth launches platform for AI agents to access voice services